Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · November 22, 2022

Outcomes of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody–Armed Activated T Cells in mCRPC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase II trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer
Clin. Cancer Res 2022 Oct 18;[EPub Ahead of Print], UN Vaishampayan, A Thakur, W Chen, A Deol, M Patel, K Dobson, B Dickow, D Schalk, A Schienschang, S Whitaker, A Polend, JA Fontana, EI Heath, LG Lum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading